首页> 美国卫生研究院文献>Critical Care Explorations >Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019
【2h】

Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019

机译:在冠状病毒病引起的急性呼吸窘迫综合征中长期应用皮质类固醇激素治疗的理由2019

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In December 2019, pneumonia associated with the novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. On March 14, 2020, the World Health Organization (WHO) declared the coronavirus outbreak a pandemic with confirmed cases in 127 countries. This unprecedented load on healthcare institutions is particularly overwhelming for ICUs and medical personnel treating mechanically ventilated patients. The occurrence rate of acute respiratory distress syndrome (ARDS) with COVID-19 infection varied between 17% and 41% ( – ). ARDS may require weeks of mechanical ventilation (MV) and is associated with an unacceptably high mortality rate. Worldwide, thousands of patients are denied life-saving support for lack of mechanical ventilators. This is unprecedented global emergency without a workable solution. Thus, any intervention directed at decreasing duration of MV and mortality could have a great impact on public health and national security.
机译:2019年12月,与新型冠状病毒病2019(COVID-19)相关的肺炎在中国武汉出现。 2020年3月14日,世界卫生组织(WHO)宣布冠状病毒爆发为大流行病,在127个国家中确诊病例。对于医疗机构来说,这种前所未有的负担使ICU和医务人员对机械通气患者的治疗尤为困难。感染COVID-19的急性呼吸窘迫综合征(ARDS)的发生率在17%至41%之间(–)。 ARDS可能需要数周的机械通气(MV),并且死亡率高得令人无法接受。在全球范围内,由于缺乏机械呼吸机,数千名患者被剥夺了挽救生命的支持。没有可行的解决方案,这是前所未有的全球紧急情况。因此,任何旨在降低MV和死亡率持续时间的干预措施都可能对公共卫生和国家安全产生重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号